Published: 2020-03-26

Evaluation of the response rate of chemo-radiation and brachytherapy in patients with locally advanced carcinoma cervix in a tertiary care center

Sukanya Semwal, Jaskaran S. Sethi, Munish Gairola, David K. Simson, Rajendra Kumar, Ankit Goyal, Apoorv Vashistha, Ankit Kumar, Palak Goel


Background: Incidence and mortality estimates are used to measure the burden of cancer in a population and survival estimates are ideal for evaluating the outcome of cancer control activities. Survival studies evaluate the quality and quantity of life of a group of patients after diagnosing the disease. The patient survival after the diagnosis of cervical cancer is indirectly influenced by socio-economic factors. The present study was carried out with an aim to evaluate the success rate of chemo-radiation followed by brachytherapy to the patients of locally advanced carcinoma (Ca.) cervix in a tertiary care center.

Methods: All cases were staged according to the International Federation of Gynaecologists and Oncologists (FIGO) staging system. To illustrate the observed survival of cancer patients Kaplan-Meier curve was plotted. All the patients, except one, completed chemo-radiation and were retrospectively analyzed for the presence of local residual disease, local recurrence, distant metastases, radiation reactions, disease-free survival, and overall survival.

Results: There were 22 patients of Carcinoma cervix reported in the radiation oncology department in the year 2018 and 2019. The overall treatment time ranged from 30 days to 178 days, with a median of 63 days. All the patients had a complete response after the treatment. The median follow-up time for all the patients was 15 months. Three patients had a metastatic recurrence and one patient developed distant metastases as well as local recurrence. Overall survival rate was 100% while the disease-free survival rate was 81.82%.

Conclusions: The response to chemo-radiation in the treatment of locally advanced Carcinoma cervix is comparable to historic data and is well tolerated.


Brachytherapy, Carcinoma cervix, Chemotherapy, Radiotherapy

Full Text:



Krishnan S, Madsen E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: implementation science priorities. Oncol. 2013 Dec;18(12):1285-97.

Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016; 37(4):278-85.

Google. Fact sheet: Cervical Cancer, 2019. Available at: Accessed 29 July 2019.

Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. HPV genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Canc Epidemio Biomark Prev. 2005;14(5):1157-64.

National Cancer Institute. Fact sheet: HPV and Cancer, 2019. Available at Accessed 28 Sep 2019.

Jain VS, Singh KK, Shrivastva R, Saumsundaram KV, Sarje MB, Jain SM. Radical radiotherapy treatment (EBRT+HDR-ICRT) of carcinoma of the uterine cervix: outcome in patients treated at the rural center in India. J Canc Res Ther. 2007; 3(4):211-6.

American Cancer Society. Fact sheet: Chemotherapy for Cervical Cancer, 2014. Available at: Accessed 31 July 2019.

Kato S, Ohno T. Cancer Imaging and Intracavitary Brachytherapy for Cervical Cancer. In: Hayat M (Eds) Methods of Cancer Diagnosis, Therapy and, Prognosis. Springer Dordrecht; 2010;6:256-262.

Selke P, Roman TN, Souhami L, Freeman CR, Clark BG, Evans MD, et al. Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1993;27:803-9.

Medscape. Fact sheet: Cervical Cancer Staging: TNM and FIGO classification of cervical cancer, 2019. Available at: Accessed 31 July 2019.

Science Blog. Fact sheet. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. Available at: . Accessed 01 Jan 2020.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. New Eng J Med 1999; 340(15):1144-53.

NCCN Guidelines. Available at: . Accessed 01 Jan 2020.

Medicine Net. Fact sheet. Hydroxyurea (Hydrea, Droxia). Available at: Accessed 25 Jan 2020.

Tan LT, Russell S, Burgess L. Acute toxicity of chemo-radiotherapy for cervical cancer: The Addenbrooke’s Experience. Clin Oncol (R Coll Radiol). 2004;16(4):255-60.

Derks K, Steenhuijsen JLG, Berg HA ven, Houterman S, Cnossen J, Harren PV, et al. Impact of brachytherapy technique (2D versus 3D) on outcome following radiotherapy of cervical cancer. J Contemp Brachyther. 2018;10(1):17-25.